{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:01Z","timestamp":1783632901552,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"internal research fund of Aprilbio Co., South Korea"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.imlet.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T08:43:37Z","timestamp":1548319417000},"page":"46-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intact bioactivities and improved pharmacokinetic of the SL335-IFN-\u03b2-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-\u03b2"],"prefix":"10.1016","volume":"207","author":[{"given":"Soo-In","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-geun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-jin","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-won","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24 Suppl. 4","key":"10.1016\/j.imlet.2019.01.009_bib0005","first-page":"S8","article-title":"Interferon-beta: mechanism of action and dosing issues","volume":"68","author":"Markowitz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.imlet.2019.01.009_bib0010","first-page":"475","article-title":"Evaluation of the human interferon system in viral disease","volume":"46","author":"Levin","year":"1981","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imlet.2019.01.009_bib0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"Suppl. 1","key":"10.1016\/j.imlet.2019.01.009_bib0020","first-page":"S17","article-title":"Interferon-\u03b2 mechanisms of action in multiple sclerosis","volume":"74","author":"Dhib-Jalbut","year":"2010","journal-title":"Neurol."},{"key":"10.1016\/j.imlet.2019.01.009_bib0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.imlet.2019.01.009_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/fps.26","article-title":"The role of interferon beta in multiple sclerosis management","volume":"7","author":"Rog","year":"2006","journal-title":"Fut. Prescrib."},{"key":"10.1016\/j.imlet.2019.01.009_bib0035","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.imlet.2019.01.009_bib0040","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1016\/S0021-9258(19)77864-8","article-title":"Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells","volume":"263","author":"Kagawa","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.imlet.2019.01.009_bib0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/287193a0","article-title":"Expression of human fibroblast interferon gene in Escherichia coli","volume":"287","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2019.01.009_bib0050","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1073\/pnas.81.18.5662","article-title":"Site-specific mutagenesis of the human fibroblast interferon gene","volume":"81","author":"Mark","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imlet.2019.01.009_bib0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00063030-199810060-00004","article-title":"Treatment of multiple sclerosis with the interferon-\u03b2s","volume":"10","author":"Herndon","year":"1988","journal-title":"BioDrugs"},{"key":"10.1016\/j.imlet.2019.01.009_bib0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s12325-014-0149-1","article-title":"Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis","volume":"31","author":"Marziniak","year":"2014","journal-title":"Adv. Therapy"},{"key":"10.1016\/j.imlet.2019.01.009_bib0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.imlet.2019.01.009_bib0070","first-page":"131","article-title":"PEGylated interferon beta-1a in the treatment of multiple sclerosis\u2013an update","volume":"7","author":"Reuss","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.imlet.2019.01.009_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/bc050237q","article-title":"N-terminally PEGylated human interferon-\u03b2-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model","volume":"17","author":"Baker","year":"2006","journal-title":"Bioconj. Chem."},{"key":"10.1016\/j.imlet.2019.01.009_bib0080","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2174\/1381612821666150302115025","article-title":"Review: modifications of human serum albumin and their binding effect","volume":"21","author":"Lee","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.imlet.2019.01.009_bib0085","doi-asserted-by":"crossref","first-page":"G352","DOI":"10.1152\/ajpgi.00286.2005","article-title":"Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces","volume":"290","author":"Kim","year":"2006","journal-title":"Am. J. Physiol. Gastrointestinal Liver Physiol."},{"key":"10.1016\/j.imlet.2019.01.009_bib0090","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","article-title":"Half-life extended biotherapeutics","volume":"16","author":"Kontermann","year":"2016","journal-title":"Exp. Opt. Biol. Ther."},{"key":"10.1016\/j.imlet.2019.01.009_bib0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2015.11.013","article-title":"Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life","volume":"169","author":"Kang","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.imlet.2019.01.009_bib0100","series-title":"Molecular Cloning: a Laboratory Manual","author":"Sambrook","year":"1989"},{"key":"10.1016\/j.imlet.2019.01.009_bib0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jbiotec.2010.09.959","article-title":"High productivity of human recombinant beta-interferon from a low-temperature perfusion culture","volume":"150","author":"Rodriguez","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.imlet.2019.01.009_bib0110","first-page":"509","volume":"150","author":"Kang","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.imlet.2019.01.009_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1600-0404.2003.00177.x","article-title":"Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?","volume":"109","author":"Casoni","year":"2004","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.imlet.2019.01.009_bib0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/protein\/gzl011","article-title":"The pharmacokinetics of an albumin-binding Fab (AB. Fab) can be modulated as a function of affinity for albumin","volume":"19","author":"Nguyen","year":"2006","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.imlet.2019.01.009_bib0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/protein\/gzm067","article-title":"Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs","volume":"21","author":"Holt","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.imlet.2019.01.009_bib0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/jpet.108.138263","article-title":"The function of the human interferon-\u03b21a glycan determined in vivo","volume":"326","author":"Dissing-Olesen","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.imlet.2019.01.009_bib0135","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1023\/A:1011974512425","article-title":"Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-\u03b2 (IFN-\u03b2)","volume":"15","author":"Runkel","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.imlet.2019.01.009_bib0140","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/10799900260475696","article-title":"A comparison of the biologic activity of two recombinant IFN-\u03b2 preparations used in the treatment of relapsing-remitting multiple sclerosis","volume":"22","author":"Antonetti","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.imlet.2019.01.009_bib0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/bp049807b","article-title":"Enhanced production of monomeric interferon-beta by CHO cells through the control of culture conditions","volume":"21","author":"Rodriguez","year":"2005","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.imlet.2019.01.009_bib0150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/btpr.8","article-title":"High yields of monomeric recombinant \u03b2-interferon from macroporous microcarrier cultures under hypothermic conditions","volume":"24","author":"Tharmalingam","year":"2008","journal-title":"Biotechnol. Prog."},{"issue":"5","key":"10.1016\/j.imlet.2019.01.009_bib0155","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/btpr.234","article-title":"Enhanced interferon\u2010\u03b2 production by CHO cells through elevated osmolality and reduced culture temperature","volume":"25","author":"Han","year":"2009","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.imlet.2019.01.009_bib0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/jir.2010.0086","article-title":"On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis","volume":"30","author":"van Beers","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.imlet.2019.01.009_bib0165","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s11095-010-0172-0","article-title":"Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice","volume":"27","author":"van Beers","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.imlet.2019.01.009_bib0170","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.23415","article-title":"Characterization and quantitation of aggregates and particles in interferon\u2010\u03b2 products: potential links between product quality attributes and immunogenicity","volume":"102","author":"Barnard","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.imlet.2019.01.009_bib0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2006.09.021","article-title":"Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay","volume":"377","author":"Massart","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.imlet.2019.01.009_bib0180","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0022-3565(24)29633-6","article-title":"Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-\u03b2-1a with preserved in vitro bioactivity","volume":"297","author":"Pepinsky","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.imlet.2019.01.009_bib0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/10799900360520423","article-title":"An IFN-\u03b2-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates","volume":"23","author":"Sung","year":"2003","journal-title":"J. Interferon Cytokine Res."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247818304486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247818304486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:34:46Z","timestamp":1759044886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247818304486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":37,"alternative-id":["S0165247818304486"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2019.01.009","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intact bioactivities and improved pharmacokinetic of the SL335-IFN-\u03b2-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-\u03b2","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}